Tumor Clinical Trials

A listing of Tumor medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 194 clinical trials
A Phase II Study Evaluating Efficacy and Safety of Hypomethylating Agent Guadecitabine in Combination with Carboplatin in Extensive Stage Small Cell Lung Cancer

The purpose of this study is to find out if the combination of guadecitabine with carboplatin is better or worse than the usual approach for small cell lung cancer.

  • 0 views
  • 19 Feb, 2024
  • 1 location
A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Placebo for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

This randomized phase III trial studies how well crizotinib works and compares it to placebo in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK).

  • 0 views
  • 19 Feb, 2024
  • 1 location
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients with Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer

The purpose of this study is to compare concurrent reduced-dose radiation therapy (RT) with cisplatin or concurrent reduced-dose radiation therapy with nivolumab to the current standard of care (standard-dose RT with cisplatin).

  • 0 views
  • 19 Feb, 2024
  • 1 location
Testing the addition of a new immunotherapy drug, Atezolizumab (MPDL3280A), to the usual chemoradiation (CRT) therapy treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)

This study is being done to answer the following question: Can we lower the chance of small cell lung cancer growing or spreading by adding an immunotherapy drug (atezolizumab) to the usual treatment for this type of cancer?

  • 0 views
  • 19 Feb, 2024
  • 1 location
Immunological Profile Changes In Patients with Advanced Non-Small Cell Lung Cancer Undergoing Treatment with Checkpoint Inhibitor Monotherapy

Researchers would like to study how certain biomarkers (signs in your genes that show how well your body responds to a treatment for a disease or condition) change before, during, and after your standard of care treatment for your non-small cell lung cancer (NSCLC). The purpose of this study is …

  • 0 views
  • 19 Feb, 2024
  • 1 location
Pilot study evaluating different methods of circulating tumor DNA quantification in radiation oncology patients

This study aims to invent a test that can see tiny pieces from your cancer (specifically DNA from your cancer) in blood and urine better than tests that can currently be done. In the future, this test can possibly be used to find a small cancer before other tests can …

  • 0 views
  • 19 Feb, 2024
  • 1 location
Phase I/II Trial Evaluating Five Fraction SABR Dose Escalation for Early Stage Squamous Cell Carcinoma of the Lung

The purpose of this study is to test whether 5 fraction stereotactic ablative body radiation (SABR) is safe and improves local control for early state squamous cell carcinoma of the lung.

  • 0 views
  • 19 Feb, 2024
  • 1 location
A Randomized Phase II Study of Partial Breast Irradiation and Sequential vs. Concurrent Chemotherapy in Women with ER Negative Early Stage Breast Cancer (PBI 3.0)

The purpose of this study is to determine whether giving partial breast irradiation and chemotherapy at the same time has the same side effects and outcomes as giving partial breast irradiation and chemotherapy at different times.

  • 0 views
  • 19 Feb, 2024
  • 1 location
Pre-Operative PARPi and Irradiation (POPI) in Women with an Incomplete Response to Neo Adjuvant Chemotherapy (NAC) for Breast Cancer.

The purpose of this study is to determine the number of participants who can handle the treatment within specific safety parameters, determine the number of participants who can handle safely the maximum tolerated dose (MTD) (within 50-200 mg/BID dose range) when combining Veliparib and radiation, as well as to identify …

  • 0 views
  • 19 Feb, 2024
  • 1 location
Phase Ib/II Study of Neoadjuvant Pembrolizumab With Gemcitabine-Cisplatin (Cisplatin-Eligible) or Gemcitabine (Cisplatin-Ineligible) in Subjects With T2-4aN0M0 Urothelial Cancer: HCRN GU14-188

This is a pre-surgical study involving subjects with muscle invasive bladder cancer, or urothelial cancer, who are candidates for neoadjuvant therapy.

  • 0 views
  • 19 Feb, 2024
  • 1 location